ID   K562 HHT
AC   CVCL_IM25
SY   K562-HHT; K562HHT
DR   Wikidata; Q54899376
RX   PubMed=7987716;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:71019; Omacetaxine mepesuccinate (Homoharringtonine; HHT).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 01-12-16; Last updated: 29-06-23; Version: 15
//
RX   PubMed=7987716;
RA   Han J.-L., Yan W.-W., Qian Q.-J., Shi H., Han M.-Z., Qiu L.-G.,
RA   Feng S.;
RT   "Two homoharringtonine resistant leukemic cell lines (K562 HHT and L1210
RT   HHT): establishment, characterization and mechanisms of action.";
RL   Zhonghua Yi Xue Za Zhi 74:424-427(1994).
//